ZabBio

ZabBio is a private, preclinical-stage biotech leveraging monoclonal antibody technology to tackle infectious diseases and reproductive health. The company's core strategy emphasizes scalable, low-cost manufacturing to serve large, price-conscious markets, particularly in low- and middle-income countries. While specific pipeline details are not publicly disclosed, its focus areas represent substantial global health burdens. As a pre-revenue entity, ZabBio's success will hinge on advancing candidates through clinical development and securing partnerships or funding for commercialization.

Monoclonal antibody discovery and development with a focus on scalable, low-cost manufacturing.

Competition includes large pharma and biotech companies developing mAbs for infectious diseases (e.g., for RSV, HIV) but typically for high-income markets. Vaccines and small molecules are alternative modalities. Few companies explicitly focus on the ultra-low-cost mAb segment, but non-profits and academic consortia are active in this space.